<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2198">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01591746</url>
  </required_header>
  <id_info>
    <org_study_id>11-001687</org_study_id>
    <nct_id>NCT01591746</nct_id>
  </id_info>
  <brief_title>Botulinum Toxin A (Botox) in Tissue Expander Breast Reconstruction</brief_title>
  <official_title>Botulinum Toxin A in Tissue Expander Breast Reconstruction: A Double-Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Each year, the number of breast cancer survivors who choose post-mastectomy breast&#xD;
      reconstruction keeps rising. Among women who elect to pursue breast reconstruction,&#xD;
      approximately 75% will choose prosthetic breast reconstruction. Implant-based breast&#xD;
      reconstruction is frequently achieved in two-stages. The first stage consists of the&#xD;
      placement of a tissue expander after mastectomy. This is followed by a period of biweekly&#xD;
      tissue expansions that can last several months. In the second stage, the tissue expander is&#xD;
      removed in a surgical procedure and replaced with a permanent breast implant. Tissue&#xD;
      expansion is a well-established breast reconstruction technique characterized by high success&#xD;
      rates and high patient satisfaction. Despite the well-recognized advantages of this&#xD;
      successful breast reconstruction technique, the subpectoral placement of a tissue expander is&#xD;
      associated with significant pain and discomfort in the immediate post-operative period and&#xD;
      during the phase of tissue expansion. Pectoralis major muscle spasm is a frequently reported&#xD;
      problem during tissue expansion. Legeby et al. recently showed that women who underwent&#xD;
      prosthetic breast reconstruction had higher pain scores and took more analgesics that those&#xD;
      who did not choose post-mastectomy reconstruction.&#xD;
&#xD;
      In the past 10 years, publications on the use of botulinum toxin A (BTX-A) for pain relief in&#xD;
      a wide array of clinical conditions have increased tremendously. BTX-A is one of the&#xD;
      neurotoxins produced by Clostridium botulinum bacteria. By reversibly inhibiting&#xD;
      neurotransmitter release, BTX-A has both analgesic and paralytic properties. The analgesic&#xD;
      action of BTX-A was initially thought to be related to its effects on muscular contraction.&#xD;
      However, a recent in vitro study of embryonic rat dorsal neurons did confirm that BTX-A&#xD;
      inhibits release of substance P, a neurotransmitter associated with pain and inflammatory&#xD;
      reactions. The presence of analgesic properties of BTX-A is increasingly supported by several&#xD;
      clinical observations: pain relief with BTX-A injections has been reported for migraine&#xD;
      headaches, chronic pelvic, chronic tennis elbow, and post-operative pain control for lower&#xD;
      limb lengthening correction, among others.&#xD;
&#xD;
      This aspect has never been studied in breast cancer survivors who elect to pursue breast&#xD;
      reconstruction with tissue expanders. Furthermore, physical function outcomes are important&#xD;
      to consider with BTX-A use because the link between temporary muscle paralysis and&#xD;
      improvements in participation in daily activities is not a given.&#xD;
&#xD;
      The investigators propose to complete a double-blinded prospective randomized controlled&#xD;
      trial of women undergoing unilateral and bilateral mastectomies with immediate placement of&#xD;
      tissue expanders, to establish the efficacy and safety of BTX-A in alleviating pain and in&#xD;
      improving physical well-being during the expansion period.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Consecutively enrolled eligible women will be randomized into one of two different treatment&#xD;
      groups: 1) Group receiving BTX-A, and 2) Group receiving a placebo. All consenting subjects&#xD;
      will be randomized to receive either a single injection of 100 units of BTX-A, or a placebo&#xD;
      (saline water), during surgery in the pectoralis major muscle on the operated side once the&#xD;
      mastectomy and the breast reconstruction have been completed. Expected duration of subject&#xD;
      participation is 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2012</start_date>
  <completion_date type="Actual">July 18, 2017</completion_date>
  <primary_completion_date type="Actual">July 18, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale</measure>
    <time_frame>preoperative visit, first postoperative visit (1-2 weeks post surgery)</time_frame>
    <description>The numeric pain intensity scale (NPIS) will be completed at the preoperative visit and again at the first postoperative visit. The NPIS is a visual analog scale (VAS) commonly used to assess clinical pain. Subjects are asked to rate their pain on a scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical Well-Being Using the BREAST-Q, Reconstruction Module</measure>
    <time_frame>first post-operative visit (1-2 weeks post surgery)</time_frame>
    <description>The Physical Well-Being scale of the BREAST-Q, Reconstruction module, will be used for this purpose. The BREAST-Q is a validated patient-reported outcome measure to accurately assess quality of life and patient satisfaction. The Reconstruction module Physical Well-Being scale has questions on the function and participation in activities before and after breast reconstruction. For this study, subjects were asked to answer 16 questions on how often they experienced each symptom, using score of 1 to 5, where 1 was none of the time and 5 was very often. Answers from these questions were combined to provide a total physical well-being score (for a total possible range of 16-80) for each patient at each visit. Lower scores reflected fewer symptoms and higher satisfaction where higher scores reflected more symptoms and less satisfaction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Initial Intraoperative Fill Volume in Milliliters (mL)</measure>
    <time_frame>Single intra-operative measurement at first surgery</time_frame>
    <description>The amount of initial intraoperative fill volume in milliliters (mL) in the tissue expander at the time of surgery divided by the manufacturers recommended total tissue expander volume will be measured. Each breast will be measured separately.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Tissue Expansion Visits</measure>
    <time_frame>up to 24 weeks post-operatively</time_frame>
    <description>The total number of tissue expansion visits completed post-operatively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Volume of Tissue Expansion</measure>
    <time_frame>Up to 24 weeks post-operatively</time_frame>
    <description>Measurement of total expansion volume in milliliters (mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Reconstruction Failure</measure>
    <time_frame>6 months after first surgery</time_frame>
    <description>The rate of reconstruction failure will be measured by the number of subjects who have tissue expander removal.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">131</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Pain, Postoperative</condition>
  <condition>BRCA1 Mutation</condition>
  <condition>BRCA2 Mutation</condition>
  <condition>Breast Diseases</condition>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Group A - Botulinum Toxin Type A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <arm_group_label>Group A - Botulinum Toxin Type A</arm_group_label>
    <other_name>BOTOX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
    <arm_group_label>Group B - Placebo</arm_group_label>
    <other_name>Sodium chloride solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women at least 18 years of age, who will undergo immediate unilateral or bilateral&#xD;
             tissue expander breast reconstruction following therapeutic skin-sparing or&#xD;
             nipple-sparing mastectomy&#xD;
&#xD;
          -  Women at least 18 years of age, who will undergo immediate bilateral tissue expanders&#xD;
             breast reconstruction following risk-reduction (prophylactic) skin-sparing or&#xD;
             nipple-sparing mastectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are unable to read or speak English&#xD;
&#xD;
          -  Breast reconstruction using the latissimus dorsi flap combined with a tissue expander&#xD;
&#xD;
          -  Documented diagnosis of chronic pain, upper limb spasticity, cervical dystonia,&#xD;
             axillary hyperhidrosis, strabismus or blepharospasm&#xD;
&#xD;
          -  Hypersensitivity to any botulinum toxin preparation or to any of the components in the&#xD;
             formulation&#xD;
&#xD;
          -  Infection at the proposed site of injection&#xD;
&#xD;
          -  Pre-existing neuromuscular disorders (including diagnosed myasthenia gravis,&#xD;
             Eaton-Lambert syndrome, or amyotrophic lateral sclerosis)&#xD;
&#xD;
          -  Aminoglycosides intake at the time of surgery (these antibiotics can potentiate the&#xD;
             effect of BTX-A)&#xD;
&#xD;
          -  Women who are pregnant or breast feeding&#xD;
&#xD;
          -  Presence of breast implants from previous breast surgery&#xD;
&#xD;
          -  Reported use of Botox within 4 months prior to planned surgical date&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Valerie Lemaine, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 13, 2012</study_first_submitted>
  <study_first_submitted_qc>May 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 4, 2012</study_first_posted>
  <results_first_submitted>April 10, 2019</results_first_submitted>
  <results_first_submitted_qc>September 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2019</results_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Valerie Lemaine</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Mastectomy</keyword>
  <keyword>Mammaplasty</keyword>
  <keyword>Breast reconstruction</keyword>
  <keyword>Tissue expansion</keyword>
  <keyword>Botulinum toxins, Type A</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Acellular dermal matrix</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Diseases</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 4, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT01591746/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group A - Botulinum Toxin Type A</title>
          <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
        </group>
        <group group_id="P2">
          <title>Group B - Placebo</title>
          <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="63"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A - Botulinum Toxin Type A</title>
          <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
        </group>
        <group group_id="B2">
          <title>Group B - Placebo</title>
          <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
            <count group_id="B2" value="63"/>
            <count group_id="B3" value="131"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.9" spread="11.1"/>
                    <measurement group_id="B2" value="48.4" spread="11.5"/>
                    <measurement group_id="B3" value="49.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="68"/>
                    <count group_id="B2" value="63"/>
                    <count group_id="B3" value="131"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.6" spread="5.9"/>
                    <measurement group_id="B2" value="26.6" spread="8.1"/>
                    <measurement group_id="B3" value="27.1" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale</title>
        <description>The numeric pain intensity scale (NPIS) will be completed at the preoperative visit and again at the first postoperative visit. The NPIS is a visual analog scale (VAS) commonly used to assess clinical pain. Subjects are asked to rate their pain on a scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.</description>
        <time_frame>preoperative visit, first postoperative visit (1-2 weeks post surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Botulinum Toxin Type A</title>
            <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
          </group>
          <group group_id="O2">
            <title>Group B - Placebo</title>
            <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Pain Scores Using a Numeric Pain Intensity Scale</title>
          <description>The numeric pain intensity scale (NPIS) will be completed at the preoperative visit and again at the first postoperative visit. The NPIS is a visual analog scale (VAS) commonly used to assess clinical pain. Subjects are asked to rate their pain on a scale from 0 to 10, where 0 is no pain and 10 is the worst pain imaginable.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1.5" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physical Well-Being Using the BREAST-Q, Reconstruction Module</title>
        <description>The Physical Well-Being scale of the BREAST-Q, Reconstruction module, will be used for this purpose. The BREAST-Q is a validated patient-reported outcome measure to accurately assess quality of life and patient satisfaction. The Reconstruction module Physical Well-Being scale has questions on the function and participation in activities before and after breast reconstruction. For this study, subjects were asked to answer 16 questions on how often they experienced each symptom, using score of 1 to 5, where 1 was none of the time and 5 was very often. Answers from these questions were combined to provide a total physical well-being score (for a total possible range of 16-80) for each patient at each visit. Lower scores reflected fewer symptoms and higher satisfaction where higher scores reflected more symptoms and less satisfaction.</description>
        <time_frame>first post-operative visit (1-2 weeks post surgery)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Botulinum Toxin Type A</title>
            <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
          </group>
          <group group_id="O2">
            <title>Group B - Placebo</title>
            <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
          </group>
        </group_list>
        <measure>
          <title>Physical Well-Being Using the BREAST-Q, Reconstruction Module</title>
          <description>The Physical Well-Being scale of the BREAST-Q, Reconstruction module, will be used for this purpose. The BREAST-Q is a validated patient-reported outcome measure to accurately assess quality of life and patient satisfaction. The Reconstruction module Physical Well-Being scale has questions on the function and participation in activities before and after breast reconstruction. For this study, subjects were asked to answer 16 questions on how often they experienced each symptom, using score of 1 to 5, where 1 was none of the time and 5 was very often. Answers from these questions were combined to provide a total physical well-being score (for a total possible range of 16-80) for each patient at each visit. Lower scores reflected fewer symptoms and higher satisfaction where higher scores reflected more symptoms and less satisfaction.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" lower_limit="57" upper_limit="68"/>
                    <measurement group_id="O2" value="60" lower_limit="57" upper_limit="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.56</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Initial Intraoperative Fill Volume in Milliliters (mL)</title>
        <description>The amount of initial intraoperative fill volume in milliliters (mL) in the tissue expander at the time of surgery divided by the manufacturers recommended total tissue expander volume will be measured. Each breast will be measured separately.</description>
        <time_frame>Single intra-operative measurement at first surgery</time_frame>
        <population>Volume measurements were not captured for all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A - Botulinum Toxin Type A</title>
            <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
          </group>
          <group group_id="O2">
            <title>Group B - Placebo</title>
            <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
          </group>
        </group_list>
        <measure>
          <title>Initial Intraoperative Fill Volume in Milliliters (mL)</title>
          <description>The amount of initial intraoperative fill volume in milliliters (mL) in the tissue expander at the time of surgery divided by the manufacturers recommended total tissue expander volume will be measured. Each breast will be measured separately.</description>
          <population>Volume measurements were not captured for all subjects.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.5" spread="23.0"/>
                    <measurement group_id="O2" value="60.4" spread="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.1" spread="23.1"/>
                    <measurement group_id="O2" value="60.0" spread="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Right breast initial percent volume expansion</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.45</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Left breast initial percent volume expansion</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Tissue Expansion Visits</title>
        <description>The total number of tissue expansion visits completed post-operatively.</description>
        <time_frame>up to 24 weeks post-operatively</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Botulinum Toxin Type A</title>
            <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
          </group>
          <group group_id="O2">
            <title>Group B - Placebo</title>
            <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Tissue Expansion Visits</title>
          <description>The total number of tissue expansion visits completed post-operatively.</description>
          <units>visits</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="4"/>
                    <measurement group_id="O2" value="3" lower_limit="2" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.43</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Volume of Tissue Expansion</title>
        <description>Measurement of total expansion volume in milliliters (mL).</description>
        <time_frame>Up to 24 weeks post-operatively</time_frame>
        <population>Volume measurement were not captured on all subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A - Botulinum Toxin Type A</title>
            <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
          </group>
          <group group_id="O2">
            <title>Group B - Placebo</title>
            <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
          </group>
        </group_list>
        <measure>
          <title>Total Volume of Tissue Expansion</title>
          <description>Measurement of total expansion volume in milliliters (mL).</description>
          <population>Volume measurement were not captured on all subjects.</population>
          <units>mL</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80" lower_limit="63" upper_limit="104"/>
                    <measurement group_id="O2" value="75" lower_limit="56" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.37</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Reconstruction Failure</title>
        <description>The rate of reconstruction failure will be measured by the number of subjects who have tissue expander removal.</description>
        <time_frame>6 months after first surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A - Botulinum Toxin Type A</title>
            <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
          </group>
          <group group_id="O2">
            <title>Group B - Placebo</title>
            <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Reconstruction Failure</title>
          <description>The rate of reconstruction failure will be measured by the number of subjects who have tissue expander removal.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
                <count group_id="O2" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from baseline until four months postoperatively for each subject, a total average of five years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A - Botulinum Toxin Type A</title>
          <description>100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride (NaCl) in the pectoralis major muscle in each operated breast&#xD;
Botulinum Toxin Type A</description>
        </group>
        <group group_id="E2">
          <title>Group B - Placebo</title>
          <description>5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast&#xD;
Placebo: 5 mL 0.9% NaCl solution to mimic Botulinum Toxin Type A</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="68"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="68"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Surgical site infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hematoma requiring reoperation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Mastectomy skin flap necrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="63"/>
              </event>
              <event>
                <sub_title>Delayed wound healing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="68"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Unplanned reoperation</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="68"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="63"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A practice change from patients receiving paravertebral blocks preoperatively to intraoperative field blocks with liposomal bupivacaine;data not collected on postoperative oral narcotic consumption;study designed to detect 25% decrease in pain score.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Valerie Lemaine, MD, MPH</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-284-2736</phone>
      <email>lemaine.valerie17@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

